Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Jones DI, Pollara JJ, Johnson-Weaver BT, LaBranche CC, Montefiori DC, Pickup DJ, Permar SR, Abraham SN, Maddaloni M, Pascual DW, Staats HF.

J Virol. 2019 Jun 28;93(14). pii: e00475-19. doi: 10.1128/JVI.00475-19. Print 2019 Jul 15.

PMID:
31068425
2.

Identification of Novel Mast Cell Activators Using Cell-Based High-Throughput Screening.

Choi HW, Chan C, Shterev ID, Lynch HE, Robinette TJ, Johnson-Weaver BT, Shi J, Sempowski GD, Kim SY, Dickson JK, Gooden DM, Abraham SN, Staats HF.

SLAS Discov. 2019 Jul;24(6):628-640. doi: 10.1177/2472555219834699. Epub 2019 Mar 27.

PMID:
30917061
3.

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.

Pollara J, Jones DI, Huffman T, Edwards RW, Dennis M, Li SH, Jha S, Goodman D, Kumar A, LaBranche CC, Montefiori DC, Fouda GG, Hope TJ, Tomaras GD, Staats HF, Ferrari G, Permar SR.

J Virol. 2019 May 1;93(10). pii: e02119-18. doi: 10.1128/JVI.02119-18. Print 2019 May 15.

4.

Nasal peanut+ CpG immunotherapy enhances peanut-specific IFN-γ in Th2 cells and IL-10 in non-Th2 cells in mice.

Johnson-Weaver BT, Sempowski GD, Staats HF.

Allergy. 2019 Feb 12. doi: 10.1111/all.13738. [Epub ahead of print] No abstract available.

PMID:
30746720
5.

MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfection.

Arifuzzaman M, Mobley YR, Choi HW, Bist P, Salinas CA, Brown ZD, Chen SL, Staats HF, Abraham SN.

Sci Adv. 2019 Jan 2;5(1):eaav0216. doi: 10.1126/sciadv.aav0216. eCollection 2019 Jan.

6.

Perivascular dendritic cells elicit anaphylaxis by relaying allergens to mast cells via microvesicles.

Choi HW, Suwanpradid J, Kim IH, Staats HF, Haniffa M, MacLeod AS, Abraham SN.

Science. 2018 Nov 9;362(6415). pii: eaao0666. doi: 10.1126/science.aao0666.

7.

Adjuvanted Immunotherapy Approaches for Peanut Allergy.

Johnson-Weaver BT, Staats HF, Burks AW, Kulis MD.

Front Immunol. 2018 Sep 25;9:2156. doi: 10.3389/fimmu.2018.02156. eCollection 2018. Review.

8.

Mast cell activators as novel immune regulators.

Johnson-Weaver B, Choi HW, Abraham SN, Staats HF.

Curr Opin Pharmacol. 2018 Aug;41:89-95. doi: 10.1016/j.coph.2018.05.004. Epub 2018 May 26. Review.

9.

Vaccine adjuvants: Softness makes it better.

Staats HF, Burkhart DJ.

Nat Mater. 2018 Jan 23;17(2):113-114. doi: 10.1038/nmat5072. No abstract available.

PMID:
29358771
10.

Effect of endotoxin and alum adjuvant vaccine on peanut allergy.

Johnson-Weaver BT, McRitchie S, Mercier KA, Pathmasiri W, Sumner SJ, Chan C, Germolec D, Kulis M, Burks AW, Staats HF.

J Allergy Clin Immunol. 2018 Feb;141(2):791-794.e8. doi: 10.1016/j.jaci.2017.07.043. Epub 2017 Sep 18. No abstract available.

11.

Assessing the satisfaction and burden within an academic animal care and use program.

Norton JN, Reynolds RP, Chan C, Valdivia RH, Staats HF.

FASEB J. 2017 Sep;31(9):3913-3921. doi: 10.1096/fj.201700072RR. Epub 2017 May 17.

PMID:
28515151
12.

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.

Jones DI, McGee CE, Sample CJ, Sempowski GD, Pickup DJ, Staats HF.

Clin Vaccine Immunol. 2016 Jul 5;23(7):648-51. doi: 10.1128/CVI.00216-16. Print 2016 Jul.

13.

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Phua KK, Staats HF, Nair SK, Leong KW.

J Control Release. 2015 Sep 10;213:e66-7. doi: 10.1016/j.jconrel.2015.05.110. Epub 2015 Aug 19. No abstract available.

PMID:
27005208
14.

Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk.

Nelson CS, Pollara J, Kunz EL, Jeffries TL Jr, Duffy R, Beck C, Stamper L, Wang M, Shen X, Pickup DJ, Staats HF, Hudgens MG, Kepler TB, Montefiori DC, Moody MA, Tomaras GD, Liao HX, Haynes BF, Ferrari G, Fouda GGA, Permar SR.

J Virol. 2016 Apr 29;90(10):4951-4965. doi: 10.1128/JVI.00335-16. Print 2016 May 15.

15.

Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface.

Samo M, Choudhary NR, Riebe KJ, Shterev I, Staats HF, Sempowski GD, Leduc I.

Vaccine. 2016 Feb 24;34(9):1193-200. doi: 10.1016/j.vaccine.2016.01.024. Epub 2016 Jan 24.

16.

Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.

Roggelin L, Vinnemeier CD, Fischer-Herr J, Johnson-Weaver BT, Rolling T, Burchard GD, Staats HF, Cramer JP.

Vaccine. 2015 Aug 7;33(33):4141-5. doi: 10.1016/j.vaccine.2015.05.080. Epub 2015 Jul 2.

PMID:
26144902
17.

Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination.

Bento D, Staats HF, Borges O.

Vaccine. 2015 Jul 17;33(31):3609-13. doi: 10.1016/j.vaccine.2015.06.037. Epub 2015 Jun 15.

PMID:
26087299
18.

Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.

Bento D, Staats HF, Gonçalves T, Borges O.

Eur J Pharm Biopharm. 2015 Jun;93:149-64. doi: 10.1016/j.ejpb.2015.03.024. Epub 2015 Mar 26.

PMID:
25818119
19.

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Phua KK, Staats HF, Leong KW, Nair SK.

Sci Rep. 2014 Jun 4;4:5128. doi: 10.1038/srep05128.

20.

Which comes first: the antigen or the adjuvant?

Permar SR, Staats HF.

J Clin Invest. 2014 Jun;124(6):2364-5. doi: 10.1172/JCI76263. Epub 2014 May 16.

21.

Salmonella typhimurium impedes innate immunity with a mast-cell-suppressing protein tyrosine phosphatase, SptP.

Choi HW, Brooking-Dixon R, Neupane S, Lee CJ, Miao EA, Staats HF, Abraham SN.

Immunity. 2013 Dec 12;39(6):1108-20. doi: 10.1016/j.immuni.2013.11.009.

22.

A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses.

Sample CJ, Hudak KE, Barefoot BE, Koci MD, Wanyonyi MS, Abraham S, Staats HF, Ramsburg EA.

Peptides. 2013 Oct;48:96-105. doi: 10.1016/j.peptides.2013.07.014. Epub 2013 Jul 26.

23.

A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating Agents.

Staats HF, Kirwan SM, Choi HW, Shelburne CP, Abraham SN, Leung GY, Chen DY.

Medchemcomm. 2013 Jan 1;4(1). doi: 10.1039/C2MD20073B.

24.

Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.

Fouda GG, Amos JD, Wilks AB, Pollara J, Ray CA, Chand A, Kunz EL, Liebl BE, Whitaker K, Carville A, Smith S, Colvin L, Pickup DJ, Staats HF, Overman G, Eutsey-Lloyd K, Parks R, Chen H, Labranche C, Barnett S, Tomaras GD, Ferrari G, Montefiori DC, Liao HX, Letvin NL, Haynes BF, Permar SR.

J Virol. 2013 Jun;87(12):6986-99. doi: 10.1128/JVI.00528-13. Epub 2013 Apr 17.

25.

Evaluation of vaccine-induced antibody responses: impact of new technologies.

Zaccaro DJ, Wagener DK, Whisnant CC, Staats HF.

Vaccine. 2013 Jun 7;31(25):2756-61. doi: 10.1016/j.vaccine.2013.03.065. Epub 2013 Apr 11.

26.

A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Gwinn WM, Johnson BT, Kirwan SM, Sobel AE, Abraham SN, Gunn MD, Staats HF.

Vaccine. 2013 Mar 1;31(11):1480-9. doi: 10.1016/j.vaccine.2013.01.012. Epub 2013 Jan 23.

27.

Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Thompson AL, Johnson BT, Sempowski GD, Gunn MD, Hou B, DeFranco AL, Staats HF.

J Immunol. 2012 Mar 15;188(6):2834-46. doi: 10.4049/jimmunol.1100254. Epub 2012 Feb 15.

28.

Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

St John AL, Chan CY, Staats HF, Leong KW, Abraham SN.

Nat Mater. 2012 Jan 22;11(3):250-7. doi: 10.1038/nmat3222.

29.

Stable dry powder formulation for nasal delivery of anthrax vaccine.

Wang SH, Kirwan SM, Abraham SN, Staats HF, Hickey AJ.

J Pharm Sci. 2012 Jan;101(1):31-47. doi: 10.1002/jps.22742. Epub 2011 Sep 8.

30.

Cytokines: the future of intranasal vaccine adjuvants.

Thompson AL, Staats HF.

Clin Dev Immunol. 2011;2011:289597. doi: 10.1155/2011/289597. Epub 2011 Jul 31. Review.

31.

Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.

Wang SH, Thompson AL, Hickey AJ, Staats HF.

Curr Top Microbiol Immunol. 2012;354:121-56. doi: 10.1007/82_2011_167. Review.

PMID:
21822816
32.

Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Staats HF, Fielhauer JR, Thompson AL, Tripp AA, Sobel AE, Maddaloni M, Abraham SN, Pascual DW.

PLoS One. 2011 Jan 27;6(1):e16532. doi: 10.1371/journal.pone.0016532.

33.

Genetic determinants of immune-response to a polysaccharide vaccine for typhoid.

Majumder PP, Staats HF, Sarkar-Roy N, Varma B, Ghosh T, Maiti S, Narayanasamy K, Whisnant CC, Stephenson JL, Wagener DK.

Hugo J. 2009 Dec;3(1-4):17-30. doi: 10.1007/s11568-010-9134-1. Epub 2010 Mar 11.

34.

Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, Moldoveanu Z, Alexander RC, Kulhavy R, Pastori C, Maboko L, Riedner G, Zhu Y, Wrinn T, Hoelscher M.

AIDS Res Hum Retroviruses. 2011 May;27(5):469-86. doi: 10.1089/aid.2010.0169. Epub 2010 Nov 22.

35.

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, Doil CR, Tlusty TG, Casey LS, Hollingshead SK, Briles DE, Dondero RS, Hickey AJ, Foster WM, Staats HF.

Vaccine. 2010 Oct 4;28(42):6901-14. doi: 10.1016/j.vaccine.2010.08.006. Epub 2010 Aug 17. Erratum in: Vaccine. 2011 Mar 24;29(15):2821.

36.

Adenovirus F protein as a delivery vehicle for botulinum B.

Clapp B, Golden S, Maddaloni M, Staats HF, Pascual DW.

BMC Immunol. 2010 Jul 7;11:36. doi: 10.1186/1471-2172-11-36.

37.

Polymer hydrogels: Chaperoning vaccines.

Staats HF, Leong KW.

Nat Mater. 2010 Jul;9(7):537-8. doi: 10.1038/nmat2788. No abstract available.

PMID:
20571480
38.

Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.

Staats HF, Kirwan SM, Whisnant CC, Stephenson JL, Wagener DK, Majumder PP.

Clin Vaccine Immunol. 2010 Mar;17(3):412-9. doi: 10.1128/CVI.00354-09. Epub 2010 Jan 27.

39.

Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues.

Shelburne CP, Nakano H, St John AL, Chan C, McLachlan JB, Gunn MD, Staats HF, Abraham SN.

Cell Host Microbe. 2009 Oct 22;6(4):331-42. doi: 10.1016/j.chom.2009.09.004.

40.

Mast cell-derived particles deliver peripheral signals to remote lymph nodes.

Kunder CA, St John AL, Li G, Leong KW, Berwin B, Staats HF, Abraham SN.

J Exp Med. 2009 Oct 26;206(11):2455-67. doi: 10.1084/jem.20090805. Epub 2009 Oct 5.

41.

The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.

McGowen AL, Hale LP, Shelburne CP, Abraham SN, Staats HF.

Vaccine. 2009 Jun 2;27(27):3544-52. doi: 10.1016/j.vaccine.2009.03.069. Epub 2009 Apr 14.

42.

Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage library.

Chen YH, Lipes BD, Kenan DJ, Staats HF, Gunn MD.

J Immunol Methods. 2009 Jan 30;340(2):144-53. doi: 10.1016/j.jim.2008.10.013. Epub 2008 Nov 17.

43.

The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.

Thompson JM, Whitmore AC, Staats HF, Johnston R.

Vaccine. 2008 Sep 15;26(39):4998-5003. doi: 10.1016/j.vaccine.2008.07.011. Epub 2008 Jul 24.

44.

Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.

Thompson JM, Whitmore AC, Staats HF, Johnston RE.

Vaccine. 2008 Aug 5;26(33):4267-75. doi: 10.1016/j.vaccine.2008.05.046. Epub 2008 Jun 9.

45.

Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.

Thompson JM, Nicholson MG, Whitmore AC, Zamora M, West A, Iwasaki A, Staats HF, Johnston RE.

J Immunol. 2008 Jul 1;181(1):574-85.

46.

An entirely cell-based system to generate single-chain antibodies against cell surface receptors.

Lipes BD, Chen YH, Ma H, Staats HF, Kenan DJ, Gunn MD.

J Mol Biol. 2008 May 30;379(2):261-72. doi: 10.1016/j.jmb.2008.03.072. Epub 2008 Apr 7.

47.

Mast cell activators: a new class of highly effective vaccine adjuvants.

McLachlan JB, Shelburne CP, Hart JP, Pizzo SV, Goyal R, Brooking-Dixon R, Staats HF, Abraham SN.

Nat Med. 2008 May;14(5):536-41. doi: 10.1038/nm1757. Epub 2008 Apr 20.

PMID:
18425129
48.

Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.

Garmise RJ, Staats HF, Hickey AJ.

AAPS PharmSciTech. 2007 Oct 12;8(4):E81. doi: 10.1208/pt0804081.

PMID:
18181542
49.
50.

Mucosal vaccine development for botulinum intoxication.

Fujihashi K, Staats HF, Kozaki S, Pascual DW.

Expert Rev Vaccines. 2007 Feb;6(1):35-45. Review.

PMID:
17280477

Supplemental Content

Loading ...
Support Center